Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Mallinckrodt plc
  6. Summary
    MNKKQ   IE00BBGT3753

MALLINCKRODT PLC

(MNKKQ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
0.19815(c) 0.1935(c) 0.1933(c) 0.1965(c) 0.19556 Last
490 731 228 609 364 309 252 725 177 784 Volume
-7.79% -2.35% -0.10% +1.66% -0.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 3 163 M - -
Net income 2019 -997 M - -
Net Debt 2019 4 673 M - -
P/E ratio 2019 -0,31x
Yield 2019 -
Sales 2020 2 213 M - -
Net income 2020 -945 M - -
Net Debt 2020 2 558 M - -
P/E ratio 2020 -0,03x
Yield 2020 -
Capitalization 16,6 M 16,6 M -
EV / Sales 2019 1,58x
EV / Sales 2020 1,17x
Nbr of Employees 3 086
Free-Float 83,8%
More Financials
Company
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and... 
Sector
Pharmaceuticals
Calendar
05/10Earnings Release
More about the company
All news about MALLINCKRODT PLC
09/03Mallinckrodt Reaches Settlement Agreement With More Creditors
DJ
09/02MALLINCKRODT : Presents Interim Results on Real World Use of Extracorporeal Photopheresis ..
PU
08/31ANI PHARMACEUTICALS : FDA Accepts Application for Cortrophin Gel Revival
DJ
08/13Mallinckrodt Provides Information to the Shareholders
CI
08/05Buxton Helmsley Sends Letter to Mallinckrodt plc
CI
08/03MALLINCKRODT : Net Debt Leverage Q2 2021 08-03-2021
PU
08/03MALLINCKRODT : Non-GAAP Definitions Q2 2021 08-03-2021
PU
08/03MALLINCKRODT : Second Quarter Financial Results (Form 8-K)
PU
08/03Mallinckrodt plc Reports Earnings Results for the Second Quarter Ended June 25, 2021
CI
08/03TRANCHE UPDATE ON MALLINCKRODT PLC ( : MNKK.Q)'s Equity Buyback Plan announced on March 1,..
CI
08/02Buxton Helmsley Provides Information to the Shareholders
CI
07/22ENDO INTERNATIONAL : Drugmaker Endo settles opioid claims by Tennessee counties, cities fo..
RE
07/21U.S. state officials urge support for landmark $26 billion opioid settlement
RE
07/21FACTBOX-Companies pay billions of dollars over role in U.S. opioid crisis
RE
07/21Drugmakers, pharmacies next targets for U.S. opioid settlements
RE
More news
News in other languages on MALLINCKRODT PLC
02/22DBV TECHNOLOGIES : nouvelle directrice juridique
2020Mallinckrodt se déclare en faillite pour régler des plaintes
2020La Vieille Europe bouge encore
2020EN DIRECT DES MARCHES : Airbus, Atos, Veolia / Suez / Engie, Carmat, Apple, KPN...
2020Erste Anleihen aus Corona-Zeit kommen in Schwierigkeiten
More news
Analyst Recommendations on MALLINCKRODT PLC
More recommendations
Chart MALLINCKRODT PLC
Duration : Period :
Mallinckrodt plc Technical Analysis Chart | MNKKQ | IE00BBGT3753 | MarketScreener
Technical analysis trends MALLINCKRODT PLC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Managers and Directors
Mark C. Trudeau President, Chief Executive Officer & Director
Bryan Marlen Reasons Chief Financial Officer & Executive Vice President
Angus C. Russell Chairman
Steven Joseph Romano Chief Scientific Officer & Executive VP
Babatunde Adekunle Otulana Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
MALLINCKRODT PLC-22.09%17
JOHNSON & JOHNSON4.16%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668